The Leukemia & Lymphoma Society (LLS) advocates for improved access to medications for patients.

LLS supports legislative efforts at both the state and federal level to limit out-of-pocket costs for blood cancer patients. To inform that work, LLS commissioned an analysis from Milliman, Inc., published in 2015, looking at how premiums might be impacted if health plans were to place limits on the cost-sharing for prescription medications. That analysis found that certain limits would significantly reduce patient out-of-pocket costs while having little impact on premiums, and also showed that premium impacts could be offset with small changes to other benefit features.

LLS recently engaged Milliman in conducting a follow-up analysis published in early 2017. The goal was to understand how cost-sharing limits for medications would impact premiums today, under current marketplace trends. In short, the findings in Milliman's latest analysis show that such limits can be done with little impact to premiums.